☰

Larry A. Harshyne, Ph.D. - Publications

Affiliations: 
2002 University of Pittsburgh, Pittsburgh, PA, United States 
Area:
Immunology
Tree Info Similar researchers PubMed Report error

36 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2022 Herbst C, Harshyne LA, Igyártó BZ. Intracellular monitoring by dendritic cells - a new way to stay informed - from a simple scavenger to an active gatherer. Frontiers in Immunology. 13: 1053582. PMID 36389660 DOI: 10.3389/fimmu.2022.1053582  0.373
2020 Flemming JP, Hill BL, Haque MW, Raad J, Bonder CS, Harshyne LA, Rodeck U, Luginbuhl A, Wahl JK, Tsai KY, Wermuth PJ, Overmiller AM, Mahoney MG. miRNA- and cytokine-associated extracellular vesicles mediate squamous cell carcinomas. Journal of Extracellular Vesicles. 9: 1790159. PMID 32944178 DOI: 10.1080/20013078.2020.1790159  0.325
2020 Luginbuhl A, Johnson JM, Harshyne L, Tuluc M, Gargano S, Leiby B, Curry JM, Cognetti DM, Axelrod RS, Bhateja P, Old MO, Rodeck U, Argiris A. Window-of-opportunity trial of nivolumab with or without the IDO inhibitor BMS-986205 in patients with resectable squamous cell carcinoma of the head and neck (SCCHN). Journal of Clinical Oncology. 38: TPS6595-TPS6595. DOI: 10.1200/Jco.2020.38.15_Suppl.Tps6595  0.396
2020 Zinner R, Axelrod R, Solomides CC, Cowan S, Leiby B, Bhatia AK, Sundermeyer ML, Hooper DC, Harshyne L, Lu-Yao GL, Quereda-Bernabeu BC, Whang SC, OHara SC, Vernau DC, Werner-Wasik M, et al. Neoadjuvant nivolumab (N) plus cisplatin (C)/pemetrexed (P) or cisplatin /gemcitabine (G) in resectable NSCLC. Journal of Clinical Oncology. 38: 9051-9051. DOI: 10.1200/Jco.2020.38.15_Suppl.9051  0.316
2020 Zinner R, Johnson JM, Tuluc M, Curry JM, Luginbuhl A, Fundakowski CC, Yampolsky A, Goldman RA, Solomides CC, Mardekian S, Tucker C, Hooper DC, Harshyne L, Arditti-Falk D, Poller D, et al. Neoadjuvant nivolumab (N) plus weekly carboplatin (C) and paclitaxel (P) in resectable locally advanced head and neck cancer. Journal of Clinical Oncology. 38: 6583-6583. DOI: 10.1200/Jco.2020.38.15_Suppl.6583  0.301
2020 Johnson JM, Bar Ad V, Lorber E, Poller D, Manukian G, Luginbuhl A, Curry JM, Cognetti DM, Keith SW, Axelrod RS, Rodeck U, Harshyne L, Argiris A. Nivolumab (Nivo) and ipilimumab (Ipi) in combination with radiotherapy (RT) in high-risk patients (pts) with locally advanced squamous cell carcinoma of the head and neck (LA SCCHN). Journal of Clinical Oncology. 38: 6577-6577. DOI: 10.1200/Jco.2020.38.15_Suppl.6577  0.355
2020 Judy KD, Andrews DW, Harshyne L, Kenyon L, Talekar K, Atsina K, Kim L, Shi W, Werner-Wasik M, Kean R, Garcia S, Pigott K, Scott CB, Hooper DC. Abstract B71: Phase 1b/2 prospective randomized trial of four autologous cell vaccine dose cohorts for initial treatment of glioblastoma Cancer Immunology Research. 8. DOI: 10.1158/2326-6074.Tumimm18-B71  0.362
2019 Lin J, Song AJ, Hoffman-Censits J, Leiby BE, Tuluc M, Shaw C, Harshyne L, Kean R, Bar-Ad V, Den RB, Hurwitz MD, Louie J, Philipose S, Deshmukh SP, Johnson JM, et al. A Pilot Study of Radiation Therapy in Combination With Pembrolizumab in Patients With Metastatic Renal Cell Cancer. American Journal of Clinical Oncology. PMID 31693508 DOI: 10.1097/Coc.0000000000000636  0.335
2019 Kumar AT, Knops A, Swendseid B, Martinez-Outschoom U, Harshyne L, Philp N, Rodeck U, Luginbuhl A, Cognetti D, Johnson J, Curry J. Prognostic Significance of Tumor-Associated Macrophage Content in Head and Neck Squamous Cell Carcinoma: A Meta-Analysis. Frontiers in Oncology. 9: 656. PMID 31396482 DOI: 10.3389/Fonc.2019.00656  0.366
2019 Topf MC, Harshyne L, Tuluc M, Mardekian S, Vimawala S, Cognetti DM, Curry JM, Rodeck U, Luginbuhl A. Loss of CD169 Subcapsular Macrophages during Metastatic Spread of Head and Neck Squamous Cell Carcinoma. Otolaryngology--Head and Neck Surgery : Official Journal of American Academy of Otolaryngology-Head and Neck Surgery. 194599819829741. PMID 30744470 DOI: 10.1177/0194599819829741  0.359
2019 Johnson JM, Bar Ad V, Lorber E, Poller D, Luginbuhl A, Curry JM, Cognetti DM, Keith SW, Axelrod RS, Zinner R, Rodeck U, Harshyne L, Argiris A. Safety of nivolumab and ipilimumab in combination with radiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (LA SCCHN). Journal of Clinical Oncology. 37: 6070-6070. DOI: 10.1200/Jco.2019.37.15_Suppl.6070  0.359
2019 Luginbuhl A, Johnson JM, Tuluc M, Mardekian S, Harshyne L, Leiby B, Zinner R, Curry JM, Cognetti DM, Rodeck U, Argiris A. Discordant treatment response in primary tumors and lymph node metastases after four weeks of preoperative PD-1 blockade in head and neck squamous cell carcinoma (HNSCC). Journal of Clinical Oncology. 37: 6016-6016. DOI: 10.1200/Jco.2019.37.15_Suppl.6016  0.416
2019 Andrews DW, Garcia S, Judy KD, Harshyne LA, Govindarajan S, Kenyon L, Talekar K, Flanders A, Atsina K, Kim L, Martinez NL, Shi W, Werner-Wasik M, Prosniak M, Curtis MT, et al. Abstract CT038: Results of a Phase Ib trial of an autologous cell vaccine for newly diagnosed glioblastoma Cancer Research. 79. DOI: 10.1158/1538-7445.Am2019-Ct038  0.352
2019 Harshyne L, Luginbuhl A, Curry JM, Kim Y, Argiris A, Shukla S, Rodeck U, Johnson JM. Immune correlates in peripheral blood samples in a preoperative window of opportunity randomized trial of nivolumab with or without tadalafil in resectable squamous cell carcinoma of the head and neck (SCCHN) Annals of Oncology. 30. DOI: 10.1093/Annonc/Mdz253.031  0.423
2019 Shukla S, Johnson JM, Curry JM, Kim Y, Argiris A, Luginbuhl A, Harshyne L, Rodeck U. Transcriptome signatures of treatment responses in a preoperative window of opportunity trial of nivolumab and tadalafil in resectable squamous cell carcinoma of the head and neck Annals of Oncology. 30. DOI: 10.1093/Annonc/Mdz252.023  0.352
2019 Luginbuhl A, Johnson J, Harshyne L, Tuluc M, Mardekian S, Leiby B, Curry J, Cognetti D, Kim Y, Mannion K, Rodeck U, Argiris A. A window of opportunity trial of preoperative nivolumab with or without tadalafil in squamous cell carcinoma of the head and neck (SCCHN): Safety, clinical, and correlative outcomes Annals of Oncology. 30: v453. DOI: 10.1093/Annonc/Mdz252.008  0.399
2018 Curry JM, Johnson J, Mollaee M, Tassone P, Amin D, Knops A, Whitaker-Menezes D, Mahoney MG, South A, Rodeck U, Zhan T, Harshyne L, Philp N, Luginbuhl A, Cognetti D, et al. Metformin Clinical Trial in HPV+ and HPV- Head and Neck Squamous Cell Carcinoma: Impact on Cancer Cell Apoptosis and Immune Infiltrate. Frontiers in Oncology. 8: 436. PMID 30364350 DOI: 10.3389/Fonc.2018.00436  0.363
2018 Md DWA, Judy K, Harshyne L, Hooper DC. Phase 1 Trial of Vaccination with Autologous Tumor Cells and Antisense Directed Against the Insulin Growth Factor Type 1 Receptor (IGF-1R AS ODN) in Patients with Recurrent Glioblastoma Jhn Journal. 13: 2. DOI: 10.29046/Jhnj.013.1.002  0.31
2017 Topf MC, Tuluc M, Harshyne LA, Luginbuhl A. Macrophage type 2 differentiation in a patient with laryngeal squamous cell carcinoma and metastatic prostate adenocarcinoma to the cervical lymph nodes. Journal For Immunotherapy of Cancer. 5: 60. PMID 28725433 DOI: 10.1186/s40425-017-0264-z  0.34
2017 Topf MC, Tuluc M, Harshyne LA, Luginbuhl A. Macrophage type 2 differentiation in a patient with laryngeal squamous cell carcinoma and metastatic prostate adenocarcinoma to the cervical lymph nodes. Journal For Immunotherapy of Cancer. 5: 60. PMID 28716144 DOI: 10.1186/S40425-017-0264-Z  0.435
2017 Overmiller AM, Pierluissi JA, Wermuth PJ, Sauma S, Martinez-Outschoorn U, Tuluc M, Luginbuhl A, Curry J, Harshyne LA, Wahl JK, South AP, Mahoney MG. Desmoglein 2 modulates extracellular vesicle release from squamous cell carcinoma keratinocytes. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. PMID 28438789 DOI: 10.1096/Fj.201601138Rr  0.388
2017 Lin J, Hoffman-Censits JH, Kelly WK, Tuluc M, Shaw C, Louie J, Harshyne L, Kean R, Bar-Ad V, Den RB, Hurwitz M, Johnson JM, Hubert C, Philipose S, Leiby BE, et al. An exploratory study to investigate the immunomodulatory activity of radiation therapy in combination with pembrolizumab in patients with renal cell cancer. Journal of Clinical Oncology. 35: 518-518. DOI: 10.1200/Jco.2017.35.6_Suppl.518  0.37
2016 Fortuna D, Cárdenas AM, Graf EH, Harshyne LA, Hooper DC, Prosniak M, Shields J, Curtis MT. Human parechovirus and enterovirus initiate distinct CNS innate immune responses: Pathogenic and diagnostic implications. Journal of Clinical Virology : the Official Publication of the Pan American Society For Clinical Virology. 86: 39-45. PMID 27914285 DOI: 10.1016/J.Jcv.2016.11.007  0.301
2016 Alexander GS, Palmer JD, Tuluc M, Lin J, Dicker AP, Bar-Ad V, Harshyne LA, Louie J, Shaw CM, Hooper DC, Lu B. Immune biomarkers of treatment failure for a patient on a phase I clinical trial of pembrolizumab plus radiotherapy. Journal of Hematology & Oncology. 9: 96. PMID 27663515 DOI: 10.1186/S13045-016-0328-4  0.366
2015 Harshyne LA, Nasca BJ, Kenyon LC, Andrews DW, Hooper DC. Serum exosomes and cytokines promote a T-helper cell type 2 environment in the peripheral blood of glioblastoma patients. Neuro-Oncology. PMID 26180083 DOI: 10.1093/Neuonc/Nov107  0.341
2015 Morin-Brureau M, Hooper KM, Prosniak M, Sauma S, Harshyne LA, Andrews DW, Hooper DC. Enhancement of glioma-specific immunity in mice by "NOBEL", an insulin-like growth factor 1 receptor antisense oligodeoxynucleotide. Cancer Immunology, Immunotherapy : Cii. 64: 447-57. PMID 25579379 DOI: 10.1007/S00262-015-1654-Z  0.397
2015 Harshyne LA, Hooper KM, Andrews EG, Nasca BJ, Kenyon LC, Andrews DW, Hooper DC. Glioblastoma exosomes and IGF-1R/AS-ODN are immunogenic stimuli in a translational research immunotherapy paradigm. Cancer Immunology, Immunotherapy : Cii. 64: 299-309. PMID 25391690 DOI: 10.1007/S00262-014-1622-Z  0.373
2015 Tao Z, Myers C, Wiedemann N, Vuagniaux G, Harshyne L, Dicker A, Hooper DC, Lu B. Abstract 283: Smac mimetic and radiotherapy synergize to enhance antitumor immunity in lung cancer by targeting immunosuppressive cells Immunology. 75: 283-283. DOI: 10.1158/1538-7445.Am2015-283  0.335
2015 Barkhouse D, Tao Z, Myers C, Wiedemann N, Gavillet B, Harshyne L, Dicker A, Hooper DC, Vuagniaux G, Lu B. Abstract A93: The Smac mimetic Debio 1143 synergizes with radiotherapy and immune checkpoint inhibitors to enhance antitumor immunity Molecular Cancer Therapeutics. 14. DOI: 10.1158/1535-7163.Targ-15-A93  0.418
2013 Prosniak M, Harshyne LA, Andrews DW, Kenyon LC, Bedelbaeva K, Apanasovich TV, Heber-Katz E, Curtis MT, Cotzia P, Hooper DC. Glioma grade is associated with the accumulation and activity of cells bearing M2 monocyte markers. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 3776-86. PMID 23741072 DOI: 10.1158/1078-0432.Ccr-12-1940  0.347
2006 Cui J, Han SY, Wang C, Su W, Harshyne L, Holgado-Madruga M, Wong AJ. c-Jun NH(2)-terminal kinase 2alpha2 promotes the tumorigenicity of human glioblastoma cells. Cancer Research. 66: 10024-31. PMID 17047065 DOI: 10.1158/0008-5472.Can-06-0136  0.332
2005 Tang J, Flomenberg P, Harshyne L, Kenyon L, Andrews DW. Glioblastoma patients exhibit circulating tumor-specific CD8+ T cells. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 11: 5292-9. PMID 16033848 DOI: 10.1158/1078-0432.Ccr-05-0545  0.435
2003 Harshyne LA, Zimmer MI, Watkins SC, Barratt-Boyes SM. A role for class A scavenger receptor in dendritic cell nibbling from live cells. Journal of Immunology (Baltimore, Md. : 1950). 170: 2302-9. PMID 12594251 DOI: 10.4049/Jimmunol.170.5.2302  0.657
2002 Barratt-Boyes SM, Zimmer MI, Harshyne L. Changes in dendritic cell migration and activation during SIV infection suggest a role in initial viral spread and eventual immunosuppression. Journal of Medical Primatology. 31: 186-93. PMID 12390541 DOI: 10.1034/J.1600-0684.2002.T01-1-02005.X  0.634
2001 Harshyne LA, Watkins SC, Gambotto A, Barratt-Boyes SM. Dendritic cells acquire antigens from live cells for cross-presentation to CTL. Journal of Immunology (Baltimore, Md. : 1950). 166: 3717-23. PMID 11238612 DOI: 10.4049/Jimmunol.166.6.3717  0.64
2000 Barratt-Boyes SM, Zimmer MI, Harshyne LA, Meyer EM, Watkins SC, Capuano S, Murphey-Corb M, Falo LD, Donnenberg AD. Maturation and trafficking of monocyte-derived dendritic cells in monkeys: implications for dendritic cell-based vaccines. Journal of Immunology (Baltimore, Md. : 1950). 164: 2487-95. PMID 10679086 DOI: 10.4049/Jimmunol.164.5.2487  0.638
Show low-probability matches.